Can a Three-Drug cocktail boost Radiation's power against a rare lymphoma?
NCT ID NCT04366128
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This trial is testing whether combining three drugs—camrelizumab, apatinib, and pegaspargase—with radiation therapy can improve outcomes for people with early-stage natural killer/T-cell lymphoma, a rare type of cancer. The study includes about 61 patients with stage IE or IIE disease who have not received prior treatment. The main goal is to see how many patients achieve a complete response (cancer disappearance) after 24 weeks of treatment, with secondary goals of measuring overall response, survival, and progression-free survival at two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of three drugs (camrelizumab, apatinib, and pegaspargase) given alongside radiation therapy
- What this could lead to
- If successful, this combination could become a more effective first-line treatment for early-stage NK/T-cell lymphoma, potentially improving complete response rates and long-term survival.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not be conclusive. The combination of drugs and radiation may cause significant side effects, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Hematology, Xinhua hospital
Shanghai, Shanghai Municipality, 200092, China
-
Shanghai Eye Ear Nose and Throat Hospital, Fudan University
Shanghai, Shanghai Municipality, 200000, China
-
Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.